American Society for Preventive Cardiology

Six barriers to prescribing PCSK9 inhibitorsA National Lipid Association survey has interesting findings on the prescription approval process for PCSK9 inhibitors.
Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.